Mitragynine vs 7OH

If you have spent any time reading about kratom alkaloids, you have probably seen the names mitragynine and 7-hydroxymitragynine used almost interchangeably. They shouldn’t be. While these two compounds share the same core chemical skeleton and come from the same plant, the differences between them are significant enough to change how laboratories detect them, how researchers classify them, and how regulators approach them.

This article breaks down the mitragynine vs 7-hydroxymitragynine comparison from the ground up. We cover the chemistry, the pharmacology, the metabolic relationship between the two, and the practical implications for laboratory work in Canada.

If you are looking for a broader overview of 7OH itself, our complete guide to 7-hydroxymitragynine covers the compound’s full background, regulatory status, and research context.

Why This Comparison Matters

The distinction between mitragynine and 7OH is not academic. It has real consequences across several areas.

For forensic laboratories, confusing one compound for the other can lead to misidentified case samples. A 2025 paper published in the journal Addiction pointed out that forensic labs using mitragynine as a surrogate marker for kratom use could incorrectly attribute 7OH-related cases to kratom, since semisynthetic 7OH products contain trace mitragynine from incomplete conversion.

For regulatory bodies, the two compounds sit in very different positions. In the United States, the Department of Health and Human Services recommended in 2025 that 7-hydroxymitragynine be placed in Schedule I, while mitragynine was not included in that recommendation. The distinction matters because it shapes policy, enforcement, and how products are classified.

For researchers studying kratom alkaloids, understanding the relationship between these compounds is foundational. You cannot properly interpret metabolism studies, receptor binding data, or analytical results without knowing what sets them apart.

What Is Mitragynine?

Mitragynine is the primary psychoactive alkaloid found in the leaves of Mitragyna speciosa, the tropical tree commonly known as kratom. It was first isolated and characterized decades before 7OH entered the scientific conversation.

Here are the core facts:

Property	Value
Chemical Name	Mitragynine
Other Names	9-methoxycorynantheidine
CAS Number	4098-40-2
Molecular Formula	C₂₃H₃₀N₂O₄
Molecular Weight	398.50 g/mol
Exact Mass	398.2206
Compound Class	Indole alkaloid (corynanthe type)
Natural Abundance	1-2% of dry leaf mass; roughly two-thirds of total alkaloid content

Mitragynine is the most abundant alkaloid in kratom by a wide margin. When someone consumes kratom leaf in any form, mitragynine is the dominant compound entering the body. It interacts with multiple receptor systems, including opioid, serotonergic, dopaminergic, and adrenergic receptors, which is part of why kratom produces a wider range of effects than a single-target compound would.

At opioid receptors specifically, mitragynine acts as a partial agonist at the mu-opioid receptor (MOR) with relatively modest binding affinity. Published research has measured its MOR efficacy at an EC₅₀ of approximately 339 nM, with a maximum efficacy (Emax) of about 34%. These numbers are important for the comparison that follows.

What Is 7-Hydroxymitragynine (7OH)?

7-Hydroxymitragynine is an oxidized form of mitragynine. It exists in trace quantities in kratom leaves but is primarily known as an active metabolite that forms when mitragynine is processed by the liver.

Property	Value
Chemical Name	7-Hydroxymitragynine
Other Names	7-OH-MIT, 7OHM, mitragynine hydroxyindolenine
CAS Number	174418-82-7
Molecular Formula	C₂₃H₃₀N₂O₅
Molecular Weight	414.49 g/mol
Exact Mass	414.2155
Compound Class	Terpenoid indole alkaloid
Natural Abundance	Less than 2% of total alkaloid content; typically below 0.05% of dry leaf mass

Scientists first described 7OH in 1994. It shares the same indole alkaloid backbone as mitragynine, but with one crucial addition: a hydroxyl group (-OH) at the C-7 position. That single oxygen atom changes the compound’s polarity, its chromatographic behavior, its receptor interactions, and its regulatory profile.

For a full breakdown of 7OH’s chemistry, detection methods, and Canadian regulatory status, see our complete 7OH guide.

Side-by-Side Chemical Comparison

Here is where the differences become concrete. Placing the two compounds next to each other reveals how a single hydroxyl group creates measurable divergence across every property that matters for research and analysis.

Property	Mitragynine	7-Hydroxymitragynine
CAS Number	4098-40-2	174418-82-7
Molecular Formula	C₂₃H₃₀N₂O₄	C₂₃H₃₀N₂O₅
Molecular Weight	398.50 g/mol	414.49 g/mol
Oxygen Count	4	5
Key Structural Feature	No hydroxyl at C-7	Hydroxyl group at C-7
Polarity	Lower	Higher
HPLC Retention Time	Longer (less polar, stronger column interaction)	Shorter (higher polarity, earlier elution)
MOR Binding Affinity (EC₅₀)	~339 nM	~34.5 nM
MOR Efficacy (Emax)	~34%	~47%
Relative Potency at MOR	1x (baseline)	~10x
Beta-Arrestin Recruitment	Not observed	Not observed
Abundance in Kratom Leaf	1-2% of dry mass	Less than 0.05% of dry mass
Stability	Relatively stable at room temperature	Degrades faster; sensitive to heat and light
Commercial Source	Extracted from kratom leaf	Semisynthetically produced from mitragynine
First Described	Early 20th century	1994 (Ponglux et al.)

Several things stand out from this comparison.

The molecular formulas differ by exactly one oxygen atom. Mitragynine is C₂₃H₃₀N₂O₄. 7-Hydroxymitragynine is C₂₃H₃₀N₂O₅. This is the hydroxyl group at C-7. The molecular weight difference (398.50 vs 414.49) is a direct result.

The polarity shift is the most consequential difference for laboratory work. The added hydroxyl group makes 7OH more polar than mitragynine. In reverse-phase HPLC (the most common analytical method for these compounds), more polar compounds interact less strongly with the nonpolar stationary phase and elute earlier. This means mitragynine and 7OH produce different retention times on the same column, which is the primary way laboratories distinguish between them.

The potency difference is roughly 10-fold. Research published in ACS Central Science measured 7OH’s EC₅₀ at the human mu-opioid receptor at 34.5 nM, compared to 339 nM for mitragynine. The Emax values also differ: 47% for 7OH versus 34% for mitragynine. Both compounds are partial agonists, but 7OH is meaningfully more potent and more efficacious at the same receptor.

Neither compound recruits beta-arrestin. This is one of their shared characteristics and the reason both have attracted attention from pharmacological researchers. Traditional opioid compounds activate the beta-arrestin signaling pathway, which is associated with side effects like respiratory depression and constipation. The absence of beta-arrestin recruitment in both mitragynine and 7OH has led some researchers to describe them as potential templates for developing analgesics with improved safety profiles.

How Mitragynine Converts to 7OH in the Body

One of the most important discoveries about these two compounds is that they are not just structurally related. They are metabolically connected. Mitragynine converts into 7-hydroxymitragynine inside the body, and this conversion appears to play a significant role in mitragynine’s overall activity.

The enzyme responsible for this conversion is cytochrome P450 3A4 (CYP3A4), a liver enzyme that metabolizes a wide range of drugs and compounds. Research published in ACS Central Science demonstrated that mitragynine undergoes CYP3A4-mediated oxidation in both mouse and human liver preparations, producing 7OH as an active metabolite.

A human pharmacokinetic study published in ACS Pharmacology & Translational Science took this further. After volunteers consumed kratom tea containing 23.6 mg of mitragynine, researchers measured peak plasma concentrations of 7OH at 12.81 ng/mL, occurring about 1.77 hours after ingestion. When the same volunteers were pretreated with itraconazole (a known CYP3A4 inhibitor), 7OH levels dropped by 56%. This confirmed that CYP3A4 is the primary enzyme driving the conversion.

This metabolic relationship has several practical implications:

For pharmacology research, it means mitragynine’s observed effects in living organisms are at least partly mediated by 7OH. The parent compound alone does not tell the full story.

For analytical chemistry, it means detecting mitragynine in biological samples does not rule out the presence of 7OH, and vice versa. Properly characterizing a sample may require testing for both compounds.

For forensic work, it means the presence of trace mitragynine in a semisynthetic 7OH product could be from incomplete conversion during manufacturing, or it could be from natural co-occurrence. Laboratories need to differentiate between these scenarios.

For drug interaction research, any compound that inhibits or induces CYP3A4 could theoretically alter the mitragynine-to-7OH conversion ratio, which could change the overall effect profile. This is an active area of study.

Receptor Binding and Pharmacological Differences

Both mitragynine and 7OH interact with opioid receptors, but their binding profiles are not identical.

Mu-opioid receptor (MOR). Both compounds act as partial agonists. Multiple studies have measured 7OH’s binding affinity at the MOR in the range of 13 to 37 nM across different methodologies. Mitragynine’s MOR affinity is considerably weaker. The functional consequence is that 7OH produces stronger MOR-mediated effects at equivalent concentrations.

Delta-opioid receptor (DOR) and kappa-opioid receptor (KOR). Both compounds act as competitive antagonists at these receptors. Published binding data for 7OH shows DOR affinity in the range of 91 to 155 nM and KOR affinity in the range of 123 to 133 nM, depending on the study.

Non-opioid receptors. This is where mitragynine diverges more clearly from 7OH. Mitragynine has documented interactions with adrenergic, serotonergic, and dopaminergic receptors. These additional receptor interactions may explain some of kratom’s more complex effect profile, including the dose-dependent stimulant and sedative properties reported in traditional use. 7OH’s non-opioid receptor interactions are less well characterized in the published literature.

Beta-arrestin pathway. As noted above, neither compound appears to recruit beta-arrestin. This shared characteristic is a point of ongoing pharmacological interest because beta-arrestin recruitment is associated with many of the adverse effects seen with traditional opioid drugs.

Natural Abundance in Kratom Leaves

The difference in natural concentration is dramatic and directly affects how each compound is sourced for research.

Mitragynine is the dominant alkaloid in kratom. It typically constitutes 1 to 2% of dry leaf mass and accounts for roughly two-thirds of the total alkaloid content. This abundance makes direct extraction from plant material practical. Most commercial mitragynine reference standards are plant-derived.

7-Hydroxymitragynine is a trace constituent. The FDA’s 2025 assessment report documented natural 7OH levels in kratom leaf samples ranging from 0.005% to a maximum of 0.21%, with an average of just 0.01%. Other published analyses consistently report 7OH at less than 0.05% of dry leaf mass.

This massive concentration gap is why 7OH is produced semisynthetically. Taking purified mitragynine and carrying out controlled oxidation in a laboratory setting is far more practical than trying to extract meaningful quantities of 7OH directly from leaves. This production method also allows for consistent purity levels and batch-to-batch reproducibility.

For laboratories sourcing 7OH reference materials in Canada, we maintain a range of calibrated 7OH tablets across multiple strength tiers, all produced with batch-level documentation.

How Laboratories Tell Them Apart

Given their structural similarity, how do laboratories reliably distinguish mitragynine from 7OH in a sample? The answer comes down to validated analytical methods and proper reference standards.

HPLC (High-Performance Liquid Chromatography) is the primary separation and identification tool. The polarity difference between the two compounds produces distinctly different retention times on a reverse-phase column. Mitragynine, being less polar, has a longer retention time. 7OH elutes earlier. By running both certified reference standards and comparing retention times, laboratories can confidently identify which compound is present.

LC-MS (Liquid Chromatography-Mass Spectrometry) adds structural confirmation. After chromatographic separation, mass spectrometry measures each compound’s molecular ion and fragmentation pattern. Mitragynine produces a molecular ion at m/z 398; 7OH produces one at m/z 414. The 16 amu difference corresponds exactly to the additional oxygen atom. Fragmentation patterns provide additional confirmation.

GC-MS (Gas Chromatography-Mass Spectrometry) is sometimes used as a complementary technique, but researchers should be aware of a documented limitation. The CFSRE (Center for Forensic Science Research and Education) reported that some kratom alkaloids, specifically dihydro-7-hydroxymitragynine, can undergo thermal conversion during GC analysis. This means LC-based methods are generally preferred when structural integrity must be preserved.

For a complete walkthrough of analytical protocols and best practices, see our dedicated 7OH detection methods guide.

Why Separate Calibration Standards Are Required

This point is worth emphasizing because it has direct practical consequences for any laboratory running 7OH analysis.

You cannot use a mitragynine reference standard to calibrate a 7OH assay, or vice versa. The retention time differences, the mass spectral differences, and the response factor differences mean that each compound requires its own dedicated calibration curve.

Laboratories that attempt to use one compound as a proxy for the other will produce inaccurate quantitative results. This is particularly problematic in forensic contexts, where quantitative accuracy can affect case outcomes, and in quality control settings, where purity determinations depend on correctly calibrated instrumentation.

Both Cayman Chemical and Santa Cruz Biotechnology supply certified reference standards for mitragynine (CAS 4098-40-2) and 7-hydroxymitragynine (CAS 174418-82-7) individually. Laboratories should maintain separate stock solutions and calibration data for each.

Implications for Canadian Researchers

For researchers working in Canada, the mitragynine vs 7OH distinction intersects with several practical considerations.

Regulatory classification. As of 2026, neither mitragynine nor 7-hydroxymitragynine is listed as a controlled substance under Canada’s Controlled Drugs and Substances Act (CDSA). However, Health Canada has not approved either compound for therapeutic use or human consumption. Research use remains the applicable framework. For a detailed breakdown of the current regulatory picture, see our 7OH legal status in Canada overview.

Sourcing and supply. Mitragynine is more widely available as a reference standard due to its natural abundance. 7OH reference materials are less common and typically more expensive because of the semisynthetic production requirement. Canadian laboratories benefit from domestic sourcing to avoid customs delays and currency conversion costs.

Reporting standards. When publishing research or submitting forensic reports, clearly specifying which compound was detected, at what concentration, and using which analytical method, prevents the kind of ambiguity that has caused problems in other jurisdictions. The forensic community’s experience with the mitragynine-as-surrogate-marker issue is a cautionary example.

Metabolism studies. Any research involving mitragynine administration to biological systems should account for the possibility of CYP3A4-mediated conversion to 7OH. Measuring only the parent compound without checking for the metabolite gives an incomplete picture.

Frequently Asked Questions

What is mitragynine?

Mitragynine is the most abundant psychoactive alkaloid in kratom (Mitragyna speciosa). It has the molecular formula C₂₃H₃₀N₂O₄ and a molecular weight of 398.50 g/mol. It makes up 1 to 2% of dry kratom leaf mass and interacts with opioid, serotonergic, dopaminergic, and adrenergic receptors. In the body, it is partially converted to 7-hydroxymitragynine by the liver enzyme CYP3A4.

What is the main difference between mitragynine and 7OH?

The primary structural difference is a hydroxyl group at the C-7 position on 7-hydroxymitragynine that is absent from mitragynine. This adds one oxygen atom to the molecule, increasing the molecular weight from 398.50 to 414.49 g/mol. This change increases polarity, shifts HPLC retention time, and results in approximately 10 times greater potency at the mu-opioid receptor.

Is 7OH just a stronger version of mitragynine?

Not exactly. While 7OH does bind to mu-opioid receptors with roughly 10-fold greater potency, the two compounds are not interchangeable. Mitragynine interacts with a broader range of receptor systems (including adrenergic, serotonergic, and dopaminergic receptors), while 7OH’s non-opioid receptor profile is less well characterized. They also differ in natural abundance, stability, production method, and analytical behavior.

Does mitragynine turn into 7OH?

Yes. The liver enzyme CYP3A4 converts mitragynine to 7-hydroxymitragynine through oxidation. Human pharmacokinetic studies have confirmed this conversion, and CYP3A4 inhibition reduces 7OH formation by approximately 56%. This metabolic relationship means 7OH functions as an active metabolite of mitragynine.

Are mitragynine and 7OH legal in Canada?

As of 2026, neither compound is scheduled under Canada’s Controlled Drugs and Substances Act. Both can be purchased for research purposes. Neither is approved by Health Canada for human consumption or therapeutic use. For current regulatory details, see our legal overview.

Can you use the same reference standard for both compounds?

No. Mitragynine and 7OH require separate certified reference standards for calibration. Their different molecular weights, polarities, retention times, and mass spectral profiles mean that using one as a proxy for the other will produce inaccurate results. Laboratories should maintain independent calibration curves for each compound.

Where can I source both compounds in Canada?

For 7OH, we offer research-grade tablets across multiple strength tiers with batch documentation. Mitragynine reference standards are available through established chemical suppliers including Cayman Chemical (CAS 4098-40-2) and Santa Cruz Biotechnology. For ordering 7OH specifically, see our guide to buying 7OH in Canada.

Disclaimer

This article is provided for educational and informational purposes only. It does not constitute medical, legal, or professional advice of any kind.

All products sold by 7OH Lab are intended for research and laboratory use only. They are not for human consumption, internal use, or medical applications.

The scientific data referenced in this article reflects published research available as of early 2026. Regulatory information reflects our understanding of the current Canadian framework and should not be relied upon as legal advice. Researchers and institutions should consult official Canadian regulatory sources for current, jurisdiction-specific guidance.